Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Triple-negative, EGFR Positive Metastatic Breast Cancer
NCT01732276Phase 2Unknown
- Sponsor
- Jiangmen Central Hospital
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in breast cancer, sponsored by Jiangmen Central Hospital. Primary endpoint: Clinical Benefit Rate at 1 month. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01732276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732276.